MatriceLab Innove

MatriceLAB Innove (MLI)’s activity is specifically devoted to the translation for Reproductive Medicine of innovations developed in Reproductive Immunology.

MLI was created in 2012 at the conclusion of the research phase to move this innovation from bench to bedside, after 10 years of fundamental research.

We develop an in vitro diagnosis using immune biomarkers to determine preventively if a woman's uterus is immunologically able to accept an embryo and if it's not the case we propose a personnalise treatment to restaure the endometrial immune equilibrium.

MLI’s final objective is to improve the live birth rate after in vitro fertilisation  through the documented care personalization by increasing very significantly the implantation rate.